ArticleScientific reports2025
Duloxetine deteriorates prefrontal noradrenergic pain facilitation, but reduces locus coeruleus activity to restore endogenous analgesia in chronic neuropathic pain state.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gabapentinoids-duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting.British journal of clinical pharmacology · 2026Review
- Pain Modulation and Central Sensitization in Painful Diabetic Peripheral Neuropathy: Updated Narrative Review and Future Directions.Journal of diabetes · 2026Review
- Characteristics of pain symptoms in Parkinson's disease.Clinical parkinsonism & related disorders · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chronic neuropathic pain increases basal noradrenaline (NA) concentrations in the spinal cord and brain. Spinal NA further increased by duloxetine (DLX) alleviates neuropathic pain, however, the roles of basal and DLX induced NA in brain regions have not been well investigated. α2-adrenoceptor antagonist, atipamezole, to the medial prefrontal cortex (mPFC) produced anti-allodynia at 6 weeks following spinal nerve ligation (SNL6W) but produced no effects in the earlier phase of SNL animals (SNL2W). The anti-allodynia effect of intraperitoneal DLX is attenuated in SNL6W, and the combination of intraperitoneal DLX and atipamezole to the mPFC enhanced the anti-allodynia in SNL6W. Intrathecal atipamezole in SNL6W reduced DLX analgesia. Microdialysis experiments revealed that DLX increased NA in the mPFC and spinal cord in the same manner in both SNL6W and SNL2W. These results suggested that the basal mPFC NA maintains neuropathic pain in SNL6W. The spinal NA increased by DLX produces analgesia, but NA in mPFC may counteract the action of spinal NA. In the locus coeruleus (LC), DLX increased NA around LC and decreased the pERK immunoreactivity to restore noxious stimuli induced analgesia. These results suggest that reduced LC activity may lead to the restoration of stimulus responsive activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.